These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 1357564)

  • 1. Serotonergic pathology is not widespread in Alzheimer patients without prominent aggressive symptoms.
    Procter AW; Francis PT; Stratmann GC; Bowen DM
    Neurochem Res; 1992 Sep; 17(9):917-22. PubMed ID: 1357564
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neurochemical characteristics of early and late onset types of Alzheimer's disease.
    Rossor MN; Iversen LL; Reynolds GP; Mountjoy CQ; Roth M
    Br Med J (Clin Res Ed); 1984 Mar; 288(6422):961-4. PubMed ID: 6142750
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Possible neurotransmitter basis of behavioral changes in Alzheimer's disease.
    Palmer AM; Stratmann GC; Procter AW; Bowen DM
    Ann Neurol; 1988 Jun; 23(6):616-20. PubMed ID: 2457353
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Topographical distribution of neurochemical changes in Alzheimer's disease.
    Procter AW; Lowe SL; Palmer AM; Francis PT; Esiri MM; Stratmann GC; Najlerahim A; Patel AJ; Hunt A; Bowen DM
    J Neurol Sci; 1988 Apr; 84(2-3):125-40. PubMed ID: 2898011
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A post-mortem study of noradrenergic, serotonergic and GABAergic neurons in Alzheimer's disease.
    Reinikainen KJ; Paljärvi L; Huuskonen M; Soininen H; Laakso M; Riekkinen PJ
    J Neurol Sci; 1988 Mar; 84(1):101-16. PubMed ID: 2452858
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gamma-aminobutyric acid concentration in brain tissue at two stages of Alzheimer's disease.
    Lowe SL; Francis PT; Procter AW; Palmer AM; Davison AN; Bowen DM
    Brain; 1988 Aug; 111 ( Pt 4)():785-99. PubMed ID: 3401683
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Human striatum: chemoarchitecture of the caudate nucleus, putamen and ventral striatum in health and Alzheimer's disease.
    Selden N; Geula C; Hersh L; Mesulam MM
    Neuroscience; 1994 Jun; 60(3):621-36. PubMed ID: 7523983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Postmortem studies of peptides in Alzheimer's disease and Huntington's disease.
    Rossor M; Emson P; Dawbarn D; Dockray G; Mountjoy C; Roth M
    Res Publ Assoc Res Nerv Ment Dis; 1986; 64():259-77. PubMed ID: 2425405
    [No Abstract]   [Full Text] [Related]  

  • 9. Galanin immunoreactivity is increased in the nucleus basalis of Meynert in Alzheimer's disease.
    Beal MF; MacGarvey U; Swartz KJ
    Ann Neurol; 1990 Aug; 28(2):157-61. PubMed ID: 1699471
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Neurotransmitters of the cerebral cortex in senile dementia of Alzheimer type.
    Rossor MN; Emson PC; Mountjoy CQ; Roth M; Iversen LL
    Exp Brain Res; 1982; Suppl 5():153-7. PubMed ID: 6129994
    [No Abstract]   [Full Text] [Related]  

  • 11. Circumscribed changes of the cerebral cortex in neuropsychiatric disorders of later life.
    Bowen DM; Najlerahim A; Procter AW; Francis PT; Murphy E
    Proc Natl Acad Sci U S A; 1989 Dec; 86(23):9504-8. PubMed ID: 2574463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Reduced somatostatin-like immunoreactivity in cerebral cortex from cases of Alzheimer disease and Alzheimer senile dementa.
    Davies P; Katzman R; Terry RD
    Nature; 1980 Nov; 288(5788):279-80. PubMed ID: 6107862
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alzheimer's disease: low cerebral somatostatin levels correlate with impaired cognitive function and cortical metabolism.
    Tamminga CA; Foster NL; Fedio P; Bird ED; Chase TN
    Neurology; 1987 Jan; 37(1):161-5. PubMed ID: 2879258
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Reduced serotonin 5-HT1A receptor binding in the temporal cortex correlates with aggressive behavior in Alzheimer disease.
    Lai MK; Tsang SW; Francis PT; Esiri MM; Keene J; Hope T; Chen CP
    Brain Res; 2003 Jun; 974(1-2):82-7. PubMed ID: 12742626
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Galanin-like immunoreactivity is unchanged in Alzheimer's disease and Parkinson's disease dementia cerebral cortex.
    Beal MF; Clevens RA; Chattha GK; MacGarvey UM; Mazurek MF; Gabriel SM
    J Neurochem; 1988 Dec; 51(6):1935-41. PubMed ID: 2460590
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Choline in Alzheimer's disease.
    Spillane JA; Goodhart MJ; White P; Bowen DM; Davison AN
    Lancet; 1977 Oct; 2(8042):826-7. PubMed ID: 71636
    [No Abstract]   [Full Text] [Related]  

  • 17. Catecholaminergic neurones assessed ante-mortem in Alzheimer's disease.
    Palmer AM; Francis PT; Bowen DM; Benton JS; Neary D; Mann DM; Snowden JS
    Brain Res; 1987 Jun; 414(2):365-75. PubMed ID: 3620938
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A post-mortem comparison of the cortical cholinergic system in Alzheimer's disease and Pick's disease.
    Wood PL; Etienne P; Lal S; Nair NP; Finlayson MH; Gauthier S; Palo J; Haltia M; Paetau A; Bird ED
    J Neurol Sci; 1983 Dec; 62(1-3):211-7. PubMed ID: 6142096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Presynaptic serotonergic markers in community-acquired cases of Alzheimer's disease: correlations with depression and neuroleptic medication.
    Chen CP; Alder JT; Bowen DM; Esiri MM; McDonald B; Hope T; Jobst KA; Francis PT
    J Neurochem; 1996 Apr; 66(4):1592-8. PubMed ID: 8627315
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Brain choline acetyltransferase activity and neuropeptide Y concentrations in Alzheimer's disease.
    Foster NL; Tamminga CA; O'Donohue TL; Tanimoto K; Bird ED; Chase TN
    Neurosci Lett; 1986 Jan; 63(1):71-5. PubMed ID: 3754039
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.